此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项评估两种剂量AP-472作为左旋多巴辅助疗法对伴有运动波动的帕金森病(PD)参与者有效性的研究

2026年10月26日 更新者:Appello Pharmaceuticals, Inc.

一项评估两种剂量AP-472作为左旋多巴辅助疗法对伴有运动波动的帕金森病(PD)参与者有效性的2期、双盲、安慰剂对照研究

This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo.

The study will last about 14 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given.

The study includes a screening period, a 4-week period during which Parkinson's medications must remain stable, and a 12-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.

研究概览

地位

招聘中

研究类型

介入性

注册 (估计的)

150

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Arkansas
      • Little Rock、Arkansas、美国、72205-5551
        • 招聘中
        • University of Arkansas for Medical Sciences (Site #208)
    • California
      • Carlsbad、California、美国、92011
        • 招聘中
        • Profound Research LLC (Site #222)
      • Los Alamitos、California、美国、90720-3108
        • 招聘中
        • Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS (Site #217)
      • Los Angeles、California、美国、90033-5310
        • 招聘中
        • Keck Medicine of USC - USC Healthcare Center 2 (Site #221)
      • Palo Alto、California、美国、94301
        • 招聘中
        • Parkinson's Research Centers of America (Site #218)
    • Colorado
      • Englewood、Colorado、美国、80113-2776
        • 招聘中
        • Rocky Mountain Clinical Research - CenExel - PPDS (Site #215)
    • Florida
      • Boca Raton、Florida、美国、33486
        • 招聘中
        • Parkinson's Disease & Movement Disorders Center of Boca Raton (Site #227)
      • Boca Raton、Florida、美国、33486
        • 招聘中
        • UM-UHealth at Boca Raton (Site #226)
      • Hallandale、Florida、美国、33009
        • 招聘中
        • Velocity Clinical Research - Hallandale Beach (Site #228)
      • Miami、Florida、美国、33136-1051
        • 招聘中
        • University of Miami (Site #220)
      • Orlando、Florida、美国、32825
        • 招聘中
        • Neurology One (Site #205)
      • Tampa、Florida、美国、33613-4808
        • 招聘中
        • USF Parkinson's Disease and Movement Disorders Center (Site #206)
    • Georgia
      • Augusta、Georgia、美国、30912-0020
        • 招聘中
        • Augusta University Medical Center (Site #212)
    • Indiana
      • Indianapolis、Indiana、美国、46256
        • 招聘中
        • Josephson Wallack Munshower Neurology PC (Site #231)
    • Kansas
      • Kansas City、Kansas、美国、66160
        • 招聘中
        • The University of Kansas (KU) (Site #216)
    • Kentucky
      • Lexington、Kentucky、美国、40536-0001
        • 招聘中
        • Kentucky Neuroscience Institute (Site #213)
    • Massachusetts
      • Boston、Massachusetts、美国、02215-5400
        • 招聘中
        • Beth Israel Deaconess Medical Center (Site #211)
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • 招聘中
        • University of Michigan Health System (UMHS) (Site #202)
      • Farmington Hills、Michigan、美国、48334-2973
        • 招聘中
        • Quest Research Institute - Alcanza - PPDS (Site #201)
    • New Mexico
      • Albuquerque、New Mexico、美国、87106
        • 招聘中
        • University of New Mexico Health Sciences Center (Site #225)
    • New York
      • New York、New York、美国、10029-6501
        • 招聘中
        • Mount Sinai School of Medicine (Site #209)
      • New York、New York、美国、10021
        • 招聘中
        • Joan and Sanford I. Weill Department of Medicine (Site #224)
    • North Carolina
      • Asheville、North Carolina、美国、28806
        • 招聘中
        • Asheville Neurology Specialists, P.A. (Site #229)
      • Durham、North Carolina、美国、27705
        • 招聘中
        • Duke Neurological Disorders Clinic (Site #210)
    • Ohio
      • Cleveland、Ohio、美国、44195-0001
        • 招聘中
        • Cleveland Clinic (Site #223)
      • Columbus、Ohio、美国、43210
        • 招聘中
        • The Ohio State University Wexner Medical Center (site #207)
    • Tennessee
      • Nashville、Tennessee、美国、37232
        • 招聘中
        • Vanderbilt University Medical Center (Site #204)
    • Texas
      • Cypress、Texas、美国、77429
        • 招聘中
        • Horizon Clinical Research: Gill Neuroscience - Houston (Site #232)
      • Round Rock、Texas、美国、78681-3578
        • 招聘中
        • Central Texas Neurology Consultants (Site #203)
    • Washington
      • Kirkland、Washington、美国、98034-3013
        • 招聘中
        • EvergreenHealth (Site #219)

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

30年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

Participants must meet all of the following criteria to take part in the study:

  1. Be a man or woman between 30 and 80 years of age at the time of screening.
  2. Have a diagnosis of Parkinson's disease, confirmed using standard medical criteria, including slowness of movement and symptoms that affect one side of the body more than the other.
  3. Have mild to moderate Parkinson's disease, defined as stage 3 or lower on the Hoehn and Yahr scale when medications are working ("ON" state).
  4. Experience an average of at least 3 hours of OFF time per day, based on home symptom diaries, with at least 2.5 hours of OFF time each day during the baseline period.
  5. Have a Montreal Cognitive Assessment (MoCA) score of 24 or higher at screening.
  6. Be able to walk independently, with or without the use of a walking aid.
  7. Be able to swallow oral medication.
  8. Have been on a stable Parkinson's medication regimen for at least 4 weeks before screening. Medications known as MAO-B inhibitors must have been stable for at least 12 weeks.
  9. Be taking levodopa at least four times daily (immediate- or controlled-release formulations) or three times daily (extended-release formulations such as Rytary or Crexont).

Key Exclusion Criteria:

Participants cannot take part in the study if any of the following apply:

  1. Have a form of parkinsonism that is not typical Parkinson's disease, such as secondary or atypical parkinsonism.
  2. Have previously received, or plan to receive during the study, advanced Parkinson's therapies such as continuous levodopa or dopamine delivery systems, or Parkinson's disease-related brain surgery.
  3. Have dyskinesias (involuntary movements) that are severe enough, in the study doctor's opinion, to interfere with participation.
  4. Have a history of only certain types of dyskinesias (such as OFF-state, diphasic, myoclonic, or dystonic dyskinesias) without typical peak-dose dyskinesias.
  5. Are currently taking medications that block dopamine, except for low-dose quetiapine (up to 50 mg per day) used for insomnia.
  6. Routinely use on-demand "rescue" Parkinson's medications more than three times per week.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:安慰剂

Oral tablet

实验性的:Low Dose

AP-472 100 mg per day

Oral tablet

Oral tablet

实验性的:High Dose

AP-472 300 mg per day

Oral tablet

研究衡量的是什么?

主要结果指标

结果测量
大体时间
AP-472与安慰剂相比,运动日记中平均每日OFF时间较基线的变化(标准化为16小时清醒时间)
大体时间:第 12 周
第 12 周

次要结果测量

结果测量
措施说明
大体时间
相对于基线的无麻烦性运动障碍的ON时间变化(标准化至16小时)
大体时间:第 12 周
第 12 周
Change from baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 2 (Motor Experiences of Daily Living (M-EDL)) score
大体时间:Week 12

For MDS-UPDRS Part II (Motor Experiences of Daily Living, M-EDL) there are 13 items each scored from 0 to 4. The total score range is from 0-52. A higher score indicates worse motor impact on daily activities; lower scores are better.

Week 12
Change from baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) summary index
大体时间:Week 12

For the Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index the score is calculated by averaging the 8 domain scores and converting them to a 0-100 scale. A higher score indicates worse health-related quality of life; lower scores are better.

Week 12
Change from baseline in MDS-UPDRS Part III (Motor Examination) score in the best ON state
大体时间:Week 12

The MDS-UPDRS Part III includes 33 items, each scored from 0 to 4. The total score range is from 0-132. A higher score indicates worse motor impairment; lower scores are better.

Week 12
Change from baseline in Epworth Sleepiness Scale (ESS) total score
大体时间:Week 12

The ESS consists of 8 items, each scored from 0 to 3. The total score range is from 0-24. Higher scores indicate greater daytime sleepiness; lower scores are better.

Week 12

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年2月25日

初级完成 (估计的)

2027年9月3日

研究完成 (估计的)

2028年1月3日

研究注册日期

首次提交

2026年1月29日

首先提交符合 QC 标准的

2026年2月19日

首次发布 (实际的)

2026年2月25日

研究记录更新

最后更新发布 (实际的)

2026年10月28日

上次提交的符合 QC 标准的更新

2026年10月26日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅